Ann: Long Covid-19 Collaboration Outcomes Presentation, page-136

I think we need to remember that the recent news is more interim than conclusive, and announcing conjecture to the world is a lot different than shouting facts from the rooftops.
I think there is some lack of correlation to time frames required, shareholders want things yesterday, and the reality is that phases, stages, and time click over at a pace that differs from manys' expectations.
And there is the key word again, Expectations.
Expectations are what cause a lot of anxiety and frustration, if we throttle down our expectations we will be less negatively affected, and live longer  

. The study has elucidated novel blood markers as potential diagnostic and therapeutic targets in the treatment of Long COVID-19 patients. Three (3) provisional patent applications have been filed in the US to seek protection for these new inventions.*

A number of targets (<15) have been identified as potentially amenable to treatment by currently available drugs or other therapeutic approaches on the market. The mechanisms of action of those drugs are known to modulate the discovered target proteins, therefore the marketers/developers of those drugs have been identified as initial prospects for partnering interest. A smaller number of diagnostic markers have been detected that could assist in the identification of Neuro Long Covid patients for better designed clinical trials and potentially for earlier treatment intervention. Accordingly, the Company also plans to review its newly generated intellectual property (IP) with targeted pharmaceutical and diagnostic companies for potential commercial discussions, noting that for these discussions to progress, the Company and potential partner companies would need to agree on licensing and/or joint development of this newly generated IP to advance as either diagnostic or therapeutic programs.

It all looks good, we need the patents locked in so more clarity to the relevant industries can be known, and we need collaborations to advance. If our collaborations expand to include commercial collaborators, terrific.
We just need to be careful not to get the cart before the horse.

Much more news to come, if we are patient we may be rewarded soon.